Currently we register substantial increase in prescription of antiplatelet therapy, due to cardiovascular and neurological
diseases. The handicap of antiplatelet therapy in clinical practice is the fact, that there are no tests available, which
could help to determine haemocoagulation parameters in such patients. Therefore gastroenterologists express their
concern about the possibility of significant bleeding complications during or after therapeutic endoscopy. On the other
hand cardiologists express their concern about interruption of antiaggregant therapy, due to thromboembolic events
with severe or fatal course.